The DOI matches its Crossref record, with a small difference in title or year; 27 of the 27 references it cites were found in a registry or an index.
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study
Open accessAbstract
Background and objectives: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate–associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial. Design, setting, participants, & measurements: In the correction phase, adult outpatients with plasma potassium ≥5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24–72 hours until normokalemic (potassium =3.5–5.0 mmol/L). Qualifying participants entered the ≤12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5–5.0 mmol/L) during the correction phase and maintenance of serum potassium ≤5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout. Results: Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age ≥65 years old; 74% had an eGFR<60 ml/min per 1.73 m 2 , and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3–12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values ≤5.1 and ≤5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor–naïve participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0–3.4 mmol/L, respectively. Conclusions: After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for ≤12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, clinical outcomes were not evaluated;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ef fi cacy and safety data beyond 1 year of treatment are not available;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with potassium binders, such as patiromer or sodium zirconium cyclosilicate, where each has been used to treat hyperkalemia associated with RAS blockade therapy for up to 12 months. 83,84”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both studies demonstrated the effectiveness of achieving normokalemia and that treatment with RAS blockade agents can be continued without treatment-related serious adverse effects.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 683
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 655
Sodium Zirconium Cyclosilicate in Hyperkalemia
Packham, D., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G. A., Qunibi, W. Y., Pérgola, P. E., & Singh, B. P. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411487 · Cited by 505
Self-citationAvosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S., Littke, T., & Viberti, G. C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 501
Kosiborod, M., Rasmussen, H. S., Lavin, P. T., Qunibi, W. Y., Spinowitz, B., Packham, D., Roger, S. D., Yang, A., Lerma, E. V., & Singh, B. P. (2014) · JAMA · doi:10.1001/jama.2014.15688 · Cited by 414
Self-citationHarel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J. M., & Bell, C. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.016 · Cited by 324
Ion-Exchange Resins for the Treatment of Hyperkalemia
Sterns, R. H., Rojas, M. P. L., Bernstein, P. L., & Chennupati, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010079 · Cited by 303
Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function
Luo, J., Brunelli, S. M., Jensen, D. E., & Yang, A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01730215 · Cited by 288
Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
Jain, N., Kotla, S. K., Little, B. B., Weideman, R. A., Brilakis, E. S., Reilly, R. F., & Banerjee, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.367 · Cited by 219
McGill, J. B., Sloan, L. A., Newman, J., Patel, S. D., Sauce, C., von Eynatten, M., & Woerle, H. (2012) · Diabetes Care · doi:10.2337/dc12-0706 · Cited by 203
Cited by
Sorted by citations
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances
Lott, C., Truhlář, A., Alfonzo, A. V. M., Barelli, A., Salvado, V. G., Hinkelbein, J., Nolan, J. P., Paal, P., Perkins, G. D., Thies, K., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.011 · Cited by 839
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Self-citation
Metadata
- Authors
- Spinowitz, B. S., Fishbane, S., Pergola, P. E., Roger, S. D., Lerma, E. V., Butler, J., von Haehling, S., Adler, S. H., Zhao, J., Singh, B., Lavin, P. T., McCullough, P. A., Kosiborod, M., Packham, D. K., & on behalf of the ZS-005 Study Investigators
- Affiliations
- New York Hospital Queens (US)
- Hofstra University (US)
- Renal Associates PA, San Antonio, Texas;
- Gosford Hospital (AU)
- University of Illinois Chicago (US)
- University of Mississippi (US)
- Universitätsmedizin Göttingen (DE)
- AstraZeneca (United States) (US)
- University of California, Irvine (US)
- Boston Biostatistics Research Foundation, Framingham, Massachusetts;
- Baylor University Medical Center (US)
- The George Institute for Global Health (AU)
- The University of Melbourne (AU)
- Corresponding author
- Spinowitz, Bruce S.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-05-20
- Volume
- 14
- Issue
- 6
- Pages
- 798-809
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC6556727
- OpenAlex
- W2946005791
- Cited by
- 198
- References
- 27
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 33 · 2023: 35 · 2022: 17 · 2021: 28 · 2020: 24 · 2019: 17
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- hyperkalemia, potassium homeostasis, renin-angiotensin-aldosterone system inhibitors, adverse events, hypokalemia, serum potassium, maintenance therapy, drug safety, renal potassium excretion, sodium zirconium cyclosilicate
- MeSH terms
- Adult, Aged, Humans, Hyperkalemia, Male, Potassium, Renin-Angiotensin System, Silicates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
